Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Post-Transplant Lymphoproliferative Disorder. According to GlobalData, Phase II drugs for ...

Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase I for Burkitt Lymphoma. According to GlobalData, Phase I drugs for Burkitt Lymphoma have a 68% ...

A new health operator is preparing to open an emergency room at the former Affinity Medical Center in Massillon. The Massillon Community Health and Innovation Center is planning to offer medical ...

Full approval is contingent upon positive results from confirmatory trials. Loncastuximab tesirine is a CD19-directed antibody and alkylating agent currently FDA-approved to treat refractory or ...

A panelist discusses how various antibody-drug conjugates, including polatuzumab vedotin, pinatuzumab vedotin, and loncastuximab, have been studied in combination with rituximab for ...

Discuss the updated results from the phase 2 study of loncastuximab + rituximab in R/R FL presented at ASH 2024 What were the key efficacy results, what about the safety profile?

Finding the Right Partner: Triplet Therapy for First-Line Advanced Biliary Tract Cancers BV combined with Len + R demonstrated significant improvements in overall survival (OS; 37% reduced risk of ...

ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of ALK+ Non–Small Cell Lung ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Suspected adverse reactions following chimeric ...

The result showed that ACRO's Human CD19, His Tag can bind FMC63 MAb with an affinity constant of 2.95 nM which is much higher than that of the other vendor. Image Credit: ACROBiosystems ...